Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2018 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces First Quarter 2018 Financial Results

PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDAActively preparing for NDA submission later this yearStrong financial position with $26.7 million in cash and no debt RESEARCH...
March 27, 2018 06:30 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™

RESEARCH TRIANGLE PARK, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
March 26, 2018 06:30 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results

Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033)NASDAQ listing in September 2017Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt ...
March 21, 2018 06:30 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK

RESEARCH TRIANGLE PARK, N.C., March 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
December 12, 2017 16:01 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...
December 08, 2017 08:54 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARKTM (a unique...
December 07, 2017 16:01 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Proposed Public Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...
November 13, 2017 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update And Reports Third Quarter 2017 Results

During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing...
October 16, 2017 06:00 ET | Source: Fennec Pharmaceuticals

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB)Company...
September 20, 2017 08:30 ET | Source: Fennec Pharmaceuticals

Fennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City

RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals, Inc. (NASDAQ:FENC) (TSX:FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the...